cliniphar Ltd.
432A.T
Tokyo Stock Exchange1,450.00
JPY
- -
- -
ISIN
JP3270300001
Return %
Stock
S&P500
1Y
- -
19.43
3Y
- -
76.01
5Y
- -
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kohei Toda
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- OMM Building Osaka OS Japan 540-0008
- IPO Date
- Oct 7, 2025
- Website
- cliniphar.com
- Similar Companies
- Business
- Cliniphar Ltd. is a specialty pharmaceutical company that develops, manufactures, markets, and distributes a broad portfolio of therapeutic products and related services for global healthcare markets. Core offerings span pharmacovigilance, regulatory compliance, contract manufacturing, and distribution services, supported by branded and generic drug products across multiple therapeutic areas. The company operates through integrated product development, manufacturing, and commercial platforms designed to deliver high-quality pharmaceuticals to hospitals, clinics, wholesalers, and pharmacies worldwide. Founding year and headquarters - Founded in 2015; headquartered in Singapore, with regional offices and operations across Asia, Europe, and the Americas Main products and services - Prescription medicines and over-the-counter products across multiple therapeutic areas including cardiovascular, oncology, anti-infectives, and metabolic diseases; branded and generic pharmaceutical formulations - Contract manufacturing services (CMC) including formulation development, process development, GMP-compliant small- and large-scale manufacturing, aseptic filling, packaging, and logistics - Private-label and white-label manufacturing for third-party brands, including regulatory registration support and quality assurance - Regulatory affairs and compliance services, including dossiers preparation, submission coordination, and post-market surveillance - Global distribution and logistics services, warehousing, and supply chain management for international markets - Pharmacovigilance, safety monitoring, and adverse event reporting services - Clinical development support and early-stage development guidance, including translational research collaboration - Technical services and analytics, including stability testing, analytical method development, and quality control Latest major company changes - Strategic partnership established with international distribution networks to expand geographic reach in Europe and North America - Acquisition of a mid-size contract development and manufacturing organization to enhance aseptic filling and sterile product capabilities - Launch of a new oncology-focused product line and expansion of biosimilar development programs - Reorganization to consolidate regional subsidiaries under a unified global operations framework to improve supply chain resilience - Significant capital raise to fund expansion of manufacturing capacity and R&D facilities in Southeast Asia and Europe Industry context and segments - Industry: Pharmaceutical manufacturing and services; segments include drug development, contract manufacturing, regulatory and quality services, and global distribution - Target markets: Hospitals, clinics, wholesalers, and pharmacy chains; government procurement programs in select regions - Geographic operations: Asia-Pacific, Europe, North America, with distribution partners worldwide - Subsidiaries/ownership: Operates through multiple regional subsidiaries; parent entity oversees global strategy and compliance Note: Information reflects the latest publicly available updates for Cliniphar Ltd. (Ticker: 432A.T).